ArticleCancer immunology research2014
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.
Article in Cancer immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 102 citations in OpenAlex.
- Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.Cancer immunology, immunotherapy : CII · 2016Trial
- Rhabdomyolysis as a Predominant Multisystem Serious Immune-Related Adverse Event Induced by Sintilimab: A Case Report and Literature Review.Cancer management and research · 2025Article
- Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.Diagnostics (Basel, Switzerland) · 2024Review
- Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy.Cancers · 2023Review
- Acute Oncologic Complications: Clinical-Therapeutic Management in Critical Care and Emergency Departments.Current oncology (Toronto, Ont.) · 2023Review
- Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.Autoimmunity reviews · 2023Review
- Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.Cancer biology & therapy · 2021Review
- Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?Gynecologic oncology reports · 2021Article
- Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography.The British journal of radiology · 2021Review
- Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.Journal of the American College of Emergency Physicians open · 2020Article
- Evaluation of Nivolumab for Ototoxic Effects: An Animal Study in Rats.The journal of international advanced otology · 2020Article
- Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass.Cureus · 2020Article
- Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.Melanoma management · 2019Review
- Treatment Strategies and Survival Trends for Anorectal Melanoma: Is it Time for a Change?World journal of surgery · 2019Article
- Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.Clinical diabetes and endocrinology · 2019Article
- Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway.OncoTargets and therapy · 2019Article
- Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.Current neurology and neuroscience reports · 2018Review
- Article
- Anorectal mucosal melanoma.Oncotarget · 2018Review
- Progressive hypoventilation due to mixed CD8Journal for immunotherapy of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Treatment with fully human monoclonal antibodies against programmed death 1 (PD1) receptor has shown great promise for a number of advanced malignancies. Although inflammatory adverse events have been well described with anti-CTL antigen 4 (CTLA4) therapy, experience with the range of adverse effects of anti-PD1 remains comparatively limited. Here, we report on a patient with advanced mucosal melanoma who received four doses of MK-3475, a fully human monoclonal antibody against PD1, and experienced a durable near-complete response but developed severe hypothyroidism, rhabdomyolysis, and acute kidney injury. To our knowledge, this is the first case reported of a patient with advanced mucosal melanoma who responded to anti-PD1 therapy. With the promising antitumor effects of anti-PD1 in a wide array of tumors, we expect an increasing number of patients to be exposed to anti-PD1 therapies. Recognition of infrequent presentations of adverse events such as elevated creatine kinase levels and thyroid disorders in patients who receive anti-PD1 therapy is important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.